Specialty & Orphan Drugs Market
完整報告名稱與涵蓋範圍
Specialty & Orphan Drugs Market Size, Share & Trends Analysis Report, By Drug Type (Orphan Drugs for Rare Diseases, Specialty Drugs for Complex Chronic Conditions, Ultra-Rare and Gene Therapy Products), By Therapeutic Area (Oncology and Hematology, Metabolic and Genetic Disorders, Neurology, Immunology and Inflammation, Infectious and Other Diseases), By Drug Modality (Small Molecules, Biologics, Cell, Gene and Oligonucleotide Therapies), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The specialty and orphan drugs market covers high-cost prescription medicines for rare diseases granted orphan designation and complex chronic conditions requiring specialty handling, monitoring or limited distribution, spanning small molecules, biologics and genetic medicines dispensed through specialty pharmacies, hospitals and home infusion. Mass-market primary care products are excluded, as are over-the-counter medicines.
Orphan and specialty products now account for a majority of new approvals and an expanding share of pharmaceutical spending, supported by regulatory incentives, accelerated pathways and pricing that reflects small populations. Growth drivers include genetic diagnosis of previously unrecognised rare diseases, gene and cell therapies with one-time price tags, expansion of specialty biologics into earlier lines and pediatric use, and payer acceptance of outcomes-based agreements. Countervailing pressures come from reforms to orphan exclusivity and pricing in the United States and Europe, payer scrutiny of ultra-high-cost therapies and biosimilar entry for older specialty biologics.
North America dominates value, Europe follows with reimbursement gates that vary by country, and Japan and China are expanding rare disease coverage through dedicated policy frameworks. Competition combines rare disease specialists, large pharmaceutical groups with acquired orphan franchises and genetic medicine developers.
The InsightAce study supplies US$ forecasts for all drug type, therapeutic area, drug modality and distribution channel and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Specialty & Orphan Drugs Market Snapshot
Chapter 4. Global Specialty & Orphan Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Drug Type Estimates & Trend Analysis
5.1. Drug Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Type:
5.2.1. Orphan Drugs for Rare Diseases
5.2.2. Specialty Drugs for Complex Chronic Conditions
5.2.3. Ultra-Rare and Gene Therapy Products
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
6.2.1. Oncology and Hematology
6.2.2. Metabolic and Genetic Disorders
6.2.3. Neurology
6.2.4. Immunology and Inflammation
6.2.5. Infectious and Other Diseases
Chapter 7. Market Segmentation 3: By Drug Modality Estimates & Trend Analysis
7.1. Drug Modality & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Modality:
7.2.1. Small Molecules
7.2.2. Biologics
7.2.3. Cell, Gene and Oligonucleotide Therapies
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Specialty Pharmacies
8.2.2. Hospital Pharmacies
8.2.3. Home Infusion and Direct Distribution
Chapter 9. Specialty & Orphan Drugs Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Vertex Pharmaceuticals Incorporated
11.2. Alexion (AstraZeneca plc)
11.3. BioMarin Pharmaceutical Inc.
11.4. Sanofi
11.5. Takeda Pharmaceutical Company Limited
11.6. Novartis AG
11.7. Roche Holding AG
11.8. Ultragenyx Pharmaceutical Inc.
11.9. Sarepta Therapeutics, Inc.
11.10. Ipsen S.A.
11.11. Sobi (Swedish Orphan Biovitrum AB)
11.12. Amgen Inc. (Horizon Therapeutics)
11.13. Jazz Pharmaceuticals plc
11.14. Pfizer Inc.
11.15. Chiesi Farmaceutici S.p.A.
圖表清單 List of Tables & Figures
Table 1. Global Specialty & Orphan Drugs Market Revenue Forecast by Drug Type, 2026-2035 (US$ Mn)
Figure 1. Global Specialty & Orphan Drugs Market Segmentation Overview
Table 2. Global Specialty & Orphan Drugs Market Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 2. Global Specialty & Orphan Drugs Market Share by Drug Type, 2026 & 2035
Table 3. Global Specialty & Orphan Drugs Market Revenue Forecast by Drug Modality, 2026-2035 (US$ Mn)
Figure 3. Orphan and Specialty Share of New Approvals and Pharmaceutical Spending, 2020-2035
Table 4. Global Specialty & Orphan Drugs Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Global Specialty & Orphan Drugs Market Share by Therapeutic Area, 2026 & 2035
Table 5. North America Specialty & Orphan Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Rare Disease Pipeline by Therapeutic Area and Modality, 2026
Table 6. Europe Specialty & Orphan Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Specialty & Orphan Drugs Growth Opportunity Analysis
Table 7. Asia Pacific Specialty & Orphan Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Pricing and Reimbursement Policy Changes Affecting Orphan Drugs by Region
Table 8. Latin America Specialty & Orphan Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Specialty & Orphan Drugs Market Participants
Table 9. Middle East & Africa Specialty & Orphan Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們